Author

Brian Durie

Observed names: B G M Durie, B. Durie, Brian B. G. Durie

Institution: Cedars-Sinai Medical Center

Observed institution: Cedars-Sinai Medical Center

OpenAlex ID: A5017112700

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

2009 · A Palumbo, O Sezer, et al. · Leukemia · 144

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)

2019 · Charalampia Kyriakou, Sean Molloy, et al. · Blood Cancer Journal · 106

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

2007 · Sundar Jagannath, Bill Bensinger, et al. · Blood · 6

P963: Evolution of Treatment Patterns and Overall Survival in Patients With Relapsed/refractory Multiple Myeloma Receiving a Second Line of Therapy Between 2012 and 2020: Analysis of the Preamble Cohort

2022 · D. Kuter, H. Goldschmidt, et al. · HemaSphere · 1

CO198 Outcomes Measured in Multiple Myeloma Trials in the Past 10 Years: Focus on Minimal Residual Disease and Therapy Response

2025 · Mimi Choon-Quinones, George D. Obeng, et al. · Value in Health

P-175 Real-World Minimal Residual Disease Testing Patterns: Findings From the Connect® MM Registry

2024 · Sundar Jagannath, Sikander Ailawadhi, et al. · Clinical Lymphoma Myeloma & Leukemia

Abstract 782: Circulating tumour DNA-based molecular response predicts treatment outcome in multiple myeloma

2023 · Sridurga Mithraprabhu, Tiffany Khong, et al. · Cancer Research

Abstract 3373: Circulating tumour DNA mutations correlate with relapse in a phase II trial of bortezomib-primary refractory multiple myeloma patients receiving salvage therapy

2022 · Sridurga Mithraprabhu, John Reynolds, et al. · Cancer Research

P965: Follow-up Analysis of the Randomized Phase Ii Trial of Bortezomib, Lenalidomide, Dexamthasone With/without Elotuzumab for Newly Diagnosed, High Risk Multiple Myeloma (swog-1211)

2022 · S. Usmani, A. Hoering, et al. · HemaSphere

Works count: 9

Citation count: 257

H-index: 3

I10-index: 2